Member Info for HedgeHogarth

I'm in no WhatsApp group - I think you are confusing me with yourself NOTPOSTING

Aldebaron - given you have posted a respectful post with no lies for a change i will afford you a response.

I would agree with you if the share price was in the 1600-2000p range right now (which is fair value imo)

JHFH has his own exit strategy - why would he sell his shares at current levels? They are hugely undervalued based on current progress.

Hemo has been a tough HOLD at times - but it has made it hrough the credit squeeze, it has hit the golden milestone that small Biotechs aim for i.e. human trials, Phase 1 trials data has been very stong so farm.

Many Biotechs fell - Hemo did not. I do not beleive in co-incidences - Vlad is getting things right, the science has never let us down and we are now on that all important tradjectory towards a lucrative endgame.

The derampers - including you and all the other identities - have tried every angle throughout the years. Posting things like this will ever make it to human trials, Hemo will go bust, Hemo is lying, Hemo CAR-T is not relevant and behind the competition. ALL OF THOSE FABRICATIONS HAVE PROVED TO BE EXACTLY THAT!

Hemo is the real deal and i an 99% confident that JHFH will be proved right to hold. I do not have the same size holding as him - but I am holding too

Justhereforhemo - long term investor, genuine, consistent and highly knowledgable about this company. i did not hear anyone trying to call him justhereforfleecing when so many here benefited from a 10-fold increase from 150p to 1700p.

notposting - even your membership name is a lie. you are a low life trying to dismiss the efforts of a a company trying to save lives. i would not ****see

pieerrce on you if you were on fire. vlad has more talent, integrity and intelligence in his fingernail that you have in your whole body

Bless their cotton socks - the manipulative parasites are working together.

JHFH - spot on as you always have been.

What a bunch of Fruit cakes

F o Stevey80 and learn to read - Aldebaran could not call a cab let alone a share price.

Saint - the dose excalation could go on for a long time - I hope it does as it would suggest it is tolerated at much higher dodages and likely to have a big impact on the efficacy.

However, with each read out on dosage excalation and efficacy the outcome is de-risked and the Big Pharma will get ever more interested. Ath, many Biotechs are getting bought before the conclusion og phase 1 trials

What a great update from Vlad

Anyone suggesting it is not a good update has a screw loose. That does not mean there are not risks - ofcourse there are risks. This is Biotech, this is investing.

But rememeber the last RNS - there was Nada/Zilch/Nothing found in the Trial to suggest any dose escalation toxicities

Great to hear they are talking with Big Pharma - remember that the trial is based at one of the leading institutions for cancer treatment and Car-T specifically.

Humongous plank of the week award goes the idiot below suggesting Governments do not want a cure for cancer...give me strength...

Is there no end to the stupidity of some people on here?

If you could hand pick a moment to invest in a Biotech - it would be about now for a company like HEMO....

Lots of news to come out on new trials and potential ASH presentation

It has real momentum following a long line of positive RNS updates

Car-T relatively de-risked at this stage of the lifecycle given results so far.

Commercial opportunity in Europe

BigPharma sniffing around most likely given the patent cliff edge.

Potential biggest game changer of them all sitting in the HEMO back pocket - fully owned by HEMO (CBR)

Investing in a company is risk and never a no brainer - but for those looking for an opportunity to make significant capital growth - all the ingredients are in place at HEMO

That sounds very very plausible WW

Yes h4h did belive todays news to be a fomaility - and has consistenly shared why he felt the share price was undervalued

For those who may have been less confident - will not have priced todays confirmation in

So Here4Hemo's recent optimism was WELL FOUNDED

And most on here feel that the share price undervalues the company

HereforHemo

You have indeed - I have found your posts to be very useful. Yes, you have been pretty bullish, but I genuinely believe you are right to be bullish.

Whether it's the FDA, Cellin Technologies, Hemo scientists and now the Data Safety Monitoring Board - they all LIKE what they see in thr Phase 1 results. It makes you wonder how many Big Pharmas are interested as it seems likely that they will love what they see.

FDA clearance to move into Paediatrics is SIGNIFICANT

DSMB clearance to increase dosage is SIGNIFICANT (no dose-limiting toxicities observed!!!!)

So what are HEMO doing now?

> Recruiting new adults for an increased dose - given the results so far, consultants will be queuing up to get their patients enrolled

> Recruiting children for the dose that has already proved very safe in adults

> Working with Made Scientific to improve the speed and cost of manufacturing HEMO Car-T - allowing Vlad to accelarte the trial

> Working with Cellin Technologies to potentially to expediate the commercialisation of HEM Car-T for European private patients.

Good luck HEMO - you are smashing it

Great update Hemo - everything is fully on track.

You have to laugh and pity the very sad troll Aldermoran - he has bleating on about the company giving in an update. Now that they do he moans that it doe not have enough news. This just goes to show how big a CLOWN he is - it does not matter what happens here, he will always trying and turn any update or the absence of an update into a negative thing.

The truth, the reality..... HEMO are on the road to riches and are moving as fast as they can

Very happy LTH

Advice taken Saint

I do not green box people generally anymore as I rarely visit - when I do I like to see what is being said by all posters

Saint - Alderbaron is a pest, a devious and nasty visitor to this board. I have to tolerate lots of his messages that rarely have a shred of truth.

It may respect it was a 'one off' post - I am perfectly entitled to vent and state some facts about AVACTA. I'm not a complete stranger to that company and have kept an eye on it - esp given that it is not dissimilar to Hemogenyx in terms of industry and goals.

I stand behind what i have written - ofcourse people can average down but it does not change the ROI on the shares bought below today's share price.

To be honest, AVACTA is an easy target. If Alderbaron continues to be a pest on this forum - fabricating FUD and distracting the forum with Avacta stories I will reserve the right to talk about AVACTA more - probably on the AVACTA board.

Wowsers - thought I would take a quick look at the activity of the forum following my rare intervention yesterday

13 posts (just yesterday!) by a very mischievious, manipulative poster by the name of Alderbaron - 1,473 words written by an anonymous poster who has nothing good to say about the company and is here to fabricate, disrupt and distract from what is a wonderful company doing wonderful things. Somewhere out there, 2 unsuspecting parents may have their prayers answered if HEMO CarT has the expected impat on their child.

Alderbaron has spent yet another day attacking Hemogenyx’s leadership and communication, accusing the CEO of lacking commercial direction and failing to plan financing properly. They repeatedly compare Hemogenyx unfavourably to Avacta, claiming Avacta is far better managed, commercially advanced, and scientifically broader in scope. They questioned Hemogenyx’s silence on trial updates, suggesting something might be wrong with patient outcomes, and mocked other posters for being biased, uninformed, or naïve. Overall, their comments portrayed deep scepticism about Hemogenyx’s management and confidence in Avacta’s prospects.

His claims are derogatory and outrageous. They are simply a fabrication to suit his nasty narrative,

Why is he constantly talking about Avacta on the Hemogeynx borad???? Here are some Avacta FACTs for him:

Anyone who invested in AVACTA between April 2022 and Feb 2024 is underwater - iro 50% down on their investment.

AVACTA net outflow is up to 5x higher than HEMO - they are still paying interest on the remaining c£20m of a £55m convertible Bond that was set-up in 2022. It is costing AVACTA iro £3m on interest payments.

AVACTA has 408m shares in issue - a 10% increase in shares YOY diluting the long term holders. It is safe to say that there is a lot of dilution to come if the company continues to spend up to £30m a year and with £20m convertible bond still to convert and frequent placings.

Raising £3m in July at 30p a share must have felt like a kick in the teeth for shareholders.

The comparison to HEMO is stark

Pretty much anyone who bought shares since June 2021 is now sitting on a profit. (Jan 2023, Feb 2024 and Sept 2025 being the only time the price as been above toda's levels since April 2021.

Hemo have made some big decisions to minimise their annual opex

HEMO have spent in the region of £30m to reach this point, AVACT have spend approx £200m

With an mCAP of £50m - the opportunity for share price growth is huge . Whereas the mCap of AVACTA is £280m. Neither company are expected to report any revenue in FY25. ALthough following the recent RNS from Hemo in respect of a potential Estonian opportunity, the next £1 of revenue may come from HEMO.

Let keep the HEMO board focused on HEMO. The merits of AVACTA can be debated on its own board. I'm sure it is a very good prospect - but it is not for me - I am attracted to the much bigger short/medium termgr

Hemogenyx Pharmaceuticals (HEMO) has long been undervalued despite clear progress. Phase 1 trial results have demonstrated not only safety but also promising efficacy—particularly the complete eradication of AML in the third patient. The recent FDA approval to test the treatment on pediatric patients further underscores the strength of the data, signaling significant potential for this groundbreaking therapy.

Yet, despite these advances, Hemogenyx remains underappreciated. A small group of anonymous posters has repeatedly tried to undermine investor confidence, spreading doubt and misinformation. These individuals are not engaging in thoughtful debate; their goal is to disrupt, create chaos, and capitalise on market uncertainty for their own gain.

What’s telling is the pattern of behaviour these disruptors follow. After positive news, such as recent RNS updates, they go silent. They are not investors with long-term conviction, but opportunists hoping to destabilize sentiment and manipulate prices. Their absence in the face of good news speaks volumes about their true motives.

The timing of news releases is typical for clinical-stage biotech companies. Six to eight weeks (or longer) between updates is common and expected. No news during these intervals should not be interpreted as bad news—yet these disruptors will attempt to exploit these quieter periods to sow fear.

The key is to ignore these distractions and focus on the fundamentals. Stay patient, read the RNS updates, and maintain a long-term perspective. Hemogenyx’s potential is clear, and those who stay the course will likely reap the rewards. Don’t let short-term disruptions cloud your judgment and risk missing out on a breakthrough opportunity.

NOTPOSTING is in above his head here methinks. I'm sure it will end well for him ;-)

Steady on Ricky!

Lets not attract too much interest at this stage - I'm still hoping to add some more later this year.

Would rather see the herd arrive after the next RNS

I agree Island girl.

I do not personally believe in charting - but i do appreciate that shares do not go up and down in a straight line.

As long as the McAP is significantly lower than the valuation I assign to Hemo (which it is) - it's all good with me.

If chartists think that Hemo looks primed for a move - all the better